Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Febuxostat Viatris (previously Febuxostat Mylan)
Febuxostat Viatris 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 23
HOS-138286 · Präparat HOS-098172
On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not
recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of
these drugs leading to myelotoxicity. In case of concomitant administration with febuxostat, the
dose of mercaptopurine/azathioprine should be reduced to the 20% or less of the previously
prescribed dose (see sections 4.4 and 5.3).
The adequacy of the proposed dose adjustment, which was based on a modelling and simulation
analysis from preclinical data in rats, was confirmed by the results of a clinical drug-drug
interaction study in healthy volunteers, receiving azathioprine 100 mg alone and a reduced dose
of azathioprine (25 mg) in combination with febuxostat (40 or 120 mg).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T12:27:00Z · SHA-256 ac16ec383402e83b4c7edeaa05de017d6cff004a74883ae519779585c1442c60 · Passage 487a6170163b3e2b1e4d205906c2bb2ee3917fb609399b2e9671f969c6b201f4 · Zeichen 29–795 im Abschnitt
Wechselwirkungen · Febuxostat Krka
Febuxostat Krka 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-290697 · Präparat HOS-287370
Mercaptopurine/azathioprine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-27T14:00:00Z · SHA-256 65ffa3574b2ffc33d32b376e5df4d980ad0dc9927e9b1489a04a25250d436e98 · Passage 3bafbf439775ca7fc312805adde5e19a3a858a58a0318f7d36471286b6d0f0c4 · Zeichen 0–27 im Abschnitt
Wechselwirkungen · Febuxostat Krka
Febuxostat Krka 80 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4–5
HOS-290700 · Präparat HOS-287370
4
On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not
recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these
drugs leading to myelotoxicity.
In case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should
be reduced to 20% or less of the previously prescribed dose (see sections 4.4 and 5.3).
The adequacy of the proposed dose adjustment, which was based on a modelling and simulation
analysis from preclinical data in rats, was confirmed by the results of a clinical drug-drug interaction
study in healthy volunteers, receiving azathioprine 100 mg alone and a reduced dose of azathioprine
(25 mg) in combination with febuxostat (40 or 120 mg).
Drug interaction studies of febuxostat with other cytotoxic chemotherapy have not been conducted. No
data is available regarding the safety of febuxostat during other cytotoxic therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-27T14:00:00Z · SHA-256 65ffa3574b2ffc33d32b376e5df4d980ad0dc9927e9b1489a04a25250d436e98 · Passage 6a5f3190fa3a5e833ddbf82f1fe6889dd7a8777cab1060db3fe01481ffebc750 · Zeichen 81–1032 im Abschnitt
Wechselwirkungen · Febuxostat Krka
Febuxostat Krka 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-290742 · Präparat HOS-287370
Mercaptopurine/azathioprine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-27T14:00:00Z · SHA-256 65ffa3574b2ffc33d32b376e5df4d980ad0dc9927e9b1489a04a25250d436e98 · Passage 3bafbf439775ca7fc312805adde5e19a3a858a58a0318f7d36471286b6d0f0c4 · Zeichen 0–27 im Abschnitt
Wechselwirkungen · Febuxostat Krka
Febuxostat Krka 120 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-290743 · Präparat HOS-287370
On the basis of the mechanism of action of febuxostat on XO inhibition concomitant use is not
recommended. Inhibition of XO by febuxostat may cause increased plasma concentrations of these
drugs leading to myelotoxicity.
In case of concomitant administration with febuxostat, the dose of mercaptopurine/azathioprine should
be reduced to the 20% or less of the previously prescribed dose (see sections 4.4 and 5.3).
The adequacy of the proposed dose adjustment, which was based on a modelling and simulation
analysis from preclinical data in rats, was confirmed by the results of a clinical drug-drug interaction
study in healthy volunteers, receiving azathioprine 100 mg alone and a reduced dose of azathioprine
(25 mg) in combination with febuxostat (40 or 120 mg).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-27T14:00:00Z · SHA-256 65ffa3574b2ffc33d32b376e5df4d980ad0dc9927e9b1489a04a25250d436e98 · Passage d85da277039e623aac83390f99acefc6066dbb48bf07451f72db6fd51ba7fdb1 · Zeichen 29–795 im Abschnitt
Gegenanzeigen · Jayempi
Jayempi 10 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 7
HOS-292434 · Präparat HOS-287680
- Hypersensitivity to the active substance azathioprine, 6-mercaptopurine (metabolite of
azathioprine) or to any of the excipients listed in section 6.1.
- Any live vaccine, especially Bacillus Calmette-Guérin (BCG), measles, mumps and rubella
(MMR), smallpox, yellow fever (see section 4.5).
- Lactation (see section 4.6).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:20:00Z · SHA-256 3f7995b31b20577b7bbea6f2fe0b3eb850ff6826804870d7be27a8d0872d31ca · Passage e49c485ca216b39b1b29545c2a09296e5aeb757e3c6cf153eb2cbafde22a7ced · Zeichen 0–347 im Abschnitt
Wechselwirkungen · Jayempi
Jayempi 10 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 11
HOS-292448 · Präparat HOS-287680
Xanthine oxidase activity is inhibited by allopurinol, oxipurinol and thiopurinol which results in
reduced conversion of biologically active 6-thioinosinic acid to biologically inactive 6-thiouric acid.
When allopurinol, oxipurinol and/or thiopurinol are given concomitantly with 6-mercaptopurine or
azathioprine, the dose of 6-mercaptopurine and azathioprine should be reduced to one quarter of the
original dose (see section 4.2). Fatal cases have been reported in patients treated concomitantly with
azathioprine and allopurinol.
Based on non-clinical data, other xanthine oxidase inhibitors, such as febuxostat, may prolong the
activity of azathioprine possibly resulting in enhanced bone marrow suppression. Concomitant
administration is not recommended as data are insufficient to determine an adequate dose reduction of
azathioprine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): allopurinol (HOS-089178) mercaptopurine (HOS-085568) xanthine (HOS-133925) febuxostat (HOS-117798)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:20:00Z · SHA-256 3f7995b31b20577b7bbea6f2fe0b3eb850ff6826804870d7be27a8d0872d31ca · Passage 3209294ed04d6b02bb36309c64b0cfbb7870cfd948d1dafa7c9787ef8c51c34f · Zeichen 2209–3049 im Abschnitt
Wechselwirkungen · Jayempi
Jayempi 10 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 12
HOS-292454 · Präparat HOS-287680
20 mg/m2 oral methotrexate increased the AUC of 6-mercaptopurine by approximately 31% and 2 or
5 g/m2 intravenous methotrexate increased the AUC of 6-mercaptopurine by 69% and 93%
respectively. Therefore, when azathioprine is administered concomitantly with high-dose
methotrexate, the dose should be adjusted to maintain a suitable white blood cell count.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mercaptopurine (HOS-085568) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T16:20:00Z · SHA-256 3f7995b31b20577b7bbea6f2fe0b3eb850ff6826804870d7be27a8d0872d31ca · Passage f0677cb211c3bf539a4c8b9fe61a057446fa0bd51ff01f58183c51cded54ef7e · Zeichen 3448–3804 im Abschnitt
Wechselwirkungen · Omvoh
Omvoh 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-144454 · Präparat HOS-099186
No interaction studies have been performed.
In clinical studies, concomitant use of corticosteroids or oral immunomodulators did not influence
the safety of mirikizumab.
Population pharmacokinetic data analyses indicated that the clearance of mirikizumab was not
impacted by concomitant administration of 5-ASAs (5-aminosalicylic acid), corticosteroids or oral
immunomodulators (azathioprine, 6-mercaptopurine, thioguanine, and methotrexate).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aminosalicylic acid (HOS-144455) mercaptopurine (HOS-085568) azathioprine (HOS-089001) thioguanine (HOS-144457) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-01T13:45:00Z · SHA-256 a0a1337182b9eab26e9e179dd792db5c1b42324a0724975c4d8b195ac2ca8e6e · Passage 288f435ce0bd4698cb26ca692f6756f1236c46562f66cdadcf994afdc9ecfbc4 · Zeichen 0–442 im Abschnitt
Wechselwirkungen · Omvoh
Omvoh 100 mg solution for injection in pre-filled syringe Omvoh 100 mg solution for injection in pre-filled pen Omvoh 200 mg solution for injection in pre-filled syringe Omvoh 200 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 27
HOS-144477 · Präparat HOS-099186
No interaction studies have been performed.
In clinical studies, concomitant use of corticosteroids or oral immunomodulators did not influence
the safety of mirikizumab.
Population pharmacokinetic data analyses indicated that the clearance of mirikizumab was not
impacted by concomitant administration of 5-ASAs (5-aminosalicylic acid), corticosteroids or oral
immunomodulators (azathioprine, 6-mercaptopurine, thioguanine, and methotrexate).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): aminosalicylic acid (HOS-144455) mercaptopurine (HOS-085568) azathioprine (HOS-089001) thioguanine (HOS-144457) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-01T13:45:00Z · SHA-256 a0a1337182b9eab26e9e179dd792db5c1b42324a0724975c4d8b195ac2ca8e6e · Passage 288f435ce0bd4698cb26ca692f6756f1236c46562f66cdadcf994afdc9ecfbc4 · Zeichen 0–442 im Abschnitt
Wechselwirkungen · Zolsketil pegylated liposomal
ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for infusion · Abschnitt 4.5 · PDF-Seite 9
HOS-146351 · Präparat HOS-099502
No formal medicinal product interaction studies have been performed with doxorubicin pegylated
liposomal, although phase II combination trials with conventional chemotherapy agents have been
conducted in patients with gynaecological malignancies. Exercise caution in the concomitant use of
medicinal products known to interact with standard doxorubicin hydrochloride. Doxorubicin pegylated
liposomal, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other
anti-cancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian
cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were
noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and
enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin
hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially
myelotoxic agents, at the same time.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): doxorubicin hydrochloride (HOS-085564) mercaptopurine (HOS-085568) cyclophosphamide (HOS-084539) doxorubicin (HOS-084538)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-16T15:10:00Z · SHA-256 749f25cb02ef3c2557fff9c44c8608815445daccd9aad038fce4e840c7fa1845 · Passage 0b9d37625b16db4ecf52c2fb81330158395a656841966e8e2e651e80dc4f39ee · Zeichen 0–1019 im Abschnitt
Wechselwirkungen · Fymskina
Fymskina 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-297593 · Präparat HOS-288598
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T14:10:00Z · SHA-256 f59c7efdb2ceb6f37831b2cf292c9cfa8761692bc301d13c52c16d4f432e3e15 · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 499–1528 im Abschnitt
Wechselwirkungen · Fymskina
Fymskina 45 mg solution for injection in pre-filled syringe Fymskina 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 25
HOS-297625 · Präparat HOS-288598
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T14:10:00Z · SHA-256 f59c7efdb2ceb6f37831b2cf292c9cfa8761692bc301d13c52c16d4f432e3e15 · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 499–1528 im Abschnitt
Wechselwirkungen · Steqeyma
Steqeyma 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-298158 · Präparat HOS-288748
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-18T10:58:00Z · SHA-256 9a3509f3b02c3fb7e75de75bcc03208fcf393a04fbbaef6c487f30c100e3060d · Passage 1160a00c4608f29067bc36e867879ffd80cb08b3f41e1bf69a2923a3206527c8 · Zeichen 552–1580 im Abschnitt
Wechselwirkungen · Steqeyma
Steqeyma 45 mg solution for injection Steqeyma 45 mg solution for injection in pre-filled syringe Steqeyma 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 30–31
HOS-298195 · Präparat HOS-288748
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
30
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-18T10:58:00Z · SHA-256 9a3509f3b02c3fb7e75de75bcc03208fcf393a04fbbaef6c487f30c100e3060d · Passage b0390391f976327df6510f61ecd5c965ac543870da497a7721408d66de24cff7 · Zeichen 499–1582 im Abschnitt
Wechselwirkungen · Steqeyma
Steqeyma 45 mg solution for injection in pre-filled pen Steqeyma 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 60–61
HOS-298232 · Präparat HOS-288748
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
60
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-18T10:58:00Z · SHA-256 9a3509f3b02c3fb7e75de75bcc03208fcf393a04fbbaef6c487f30c100e3060d · Passage 91e2078f78501470b4ce4e07cff6287db5eff7d966050c500f30c4ae764fcea4 · Zeichen 499–1582 im Abschnitt
Wechselwirkungen · Wezenla
WEZENLA 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-151578 · Präparat HOS-100575
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 1160a00c4608f29067bc36e867879ffd80cb08b3f41e1bf69a2923a3206527c8 · Zeichen 498–1526 im Abschnitt
Wechselwirkungen · Wezenla
WEZENLA 45 mg solution for injection WEZENLA 45 mg solution for injection in pre-filled syringe WEZENLA 90 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 28
HOS-151625 · Präparat HOS-100575
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 1160a00c4608f29067bc36e867879ffd80cb08b3f41e1bf69a2923a3206527c8 · Zeichen 498–1526 im Abschnitt
Wechselwirkungen · Wezenla
WEZENLA 45 mg solution for injection in pre-filled pen WEZENLA 90 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 55
HOS-151658 · Präparat HOS-100575
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs,
6-mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:50:00Z · SHA-256 ee8a4a8f48f02ce6abe6b0d6d8b9c74092ca858a6dbb9266fd0c8cbbf48dea12 · Passage 509d6d92dbc48f1b359d8b9cd57701ef0c13ee00b8d9b7ec2dd79e7280071ea4 · Zeichen 498–1393 im Abschnitt
Wechselwirkungen · Pyzchiva
Pyzchiva 130 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6
HOS-151980 · Präparat HOS-100665
In the population pharmacokinetic analyses of the phase 3 studies, the effect of the most frequently
used concomitant medicinal products in patients with psoriasis (including paracetamol, ibuprofen,
acetylsalicylic acid, metformin, atorvastatin, levothyroxine) on pharmacokinetics of ustekinumab was
explored. There were no indications of an interaction with these concomitantly administered medicinal
products. The basis for this analysis was that at least 100 patients (> 5% of the studied population)
were treated concomitantly with these medicinal products for at least 90% of the study period. The
pharmacokinetics of ustekinumab was not impacted by concomitant use of MTX, NSAIDs, 6-
mercaptopurine, azathioprine and oral corticosteroids in patients with psoriatic arthritis, Crohn’s
disease or ulcerative colitis, or prior exposure to anti-TNFα agents, in patients with psoriatic arthritis
or Crohn’s disease or by prior exposure to biologics (i.e. anti-TNFα agents and/or vedolizumab) in
patients with ulcerative colitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) atorvastatin (HOS-086304) mercaptopurine (HOS-085568) vedolizumab (HOS-120460) azathioprine (HOS-089001) metformin (HOS-091032) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T14:40:00Z · SHA-256 24f42a13e263361e45daf03240bd1f30ff701ef234e4b135f72f1f3a44cecfae · Passage d7992329e08441a34876eaaebb05cd7e3c6d36484de465d2bb947d8ed5148c63 · Zeichen 502–1531 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.